Literature DB >> 10833552

Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo.

K J Carpenter1, V Chapman, A H Dickenson.   

Abstract

This study aims to assess whether the antinociceptive actions of methadone are mediated solely through opioid mechanisms, or whether its reported affinity for NMDA receptors has physiological relevance in vivo. Methadone is a mu-opioid receptor agonist reported to relieve pain unresponsive to other opioids. It is a racemic mixture comprising d- and l-optical isomers; the d-isomer has a lower affinity for opioid receptors, and both also exhibit NMDA receptor binding, likely to indicate antagonist activity. d -Methadone is antinociceptive in behavioural studies via non-opioid mechanisms, which could include functional NMDA receptor-blocking activity. Here we investigate the ability of d - and dl -methadone to inhibit noxious and innocuous electrically-evoked responses of dorsal horn neurones in the anaesthetized rat. Racemic methadone (5, 25, 50, 250 microg) applied spinally, dose-relatedly inhibited the C-fibre evoked response, input and wind-up of the neurones, with a profile resembling that of morphine. d-Methadone (5, 25, 50, 250, 500 microg) was also inhibitory, although less potent by a factor of between 13 and 48 depending on the neuronal measure; its profile of inhibition resembled that of the racemic mixture rather than an NMDA receptor antagonist. Both compounds had minimal effects on Abeta-fibre-evoked activity. The inhibitory effects of both d - and dl -methadone on noxious-evoked activity were naloxone reversible. The naloxone reversibility of d -methadone inhibitions is best interpreted as indicative of a purely opioid mechanism of action. However, the ability of naloxone to reverse the effects of d -methadone may also reflect a degree of synergy between weak NMDA antagonist and opioid agonist activity. Copyright 2000 European Federation of Chapters of the International Association for the Study of Pain Copyright 2000 European Federation of Chapters of the International Association for the Study of Pain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833552     DOI: 10.1053/eujp.1999.0147

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  7 in total

1.  Characterization of the antinociceptive effects of the individual isomers of methadone after acute and chronic administrations.

Authors:  Richard W Morgan; Katherine L Nicholson
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

2.  Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.

Authors:  Anne M Neumann; Richard D Blondell; Rachel A Hoopsick; Gregory G Homish
Journal:  J Addict Dis       Date:  2019-11-27

3.  [Opioid-induced analgesia and hyperalgesia].

Authors:  W Koppert
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

4.  A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.

Authors:  Anne M Neumann; Richard D Blondell; Urmo Jaanimägi; Amanda K Giambrone; Gregory G Homish; Jacqueline R Lozano; Urszula Kowalik; Mohammadreza Azadfard
Journal:  J Addict Dis       Date:  2013

Review 5.  [Opioid-induced hyperalgesia. Pathophysiology and clinical relevance].

Authors:  W Koppert
Journal:  Anaesthesist       Date:  2004-05       Impact factor: 1.041

6.  Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids.

Authors:  Tigran Makunts; Andrew U; Rabia S Atayee; Ruben Abagyan
Journal:  Sci Rep       Date:  2019-08-28       Impact factor: 4.379

7.  Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist.

Authors:  Seira Doi; Tomohisa Mori; Naoki Uzawa; Takamichi Arima; Tomoyuki Takahashi; Masashi Uchida; Ayaka Yawata; Michiko Narita; Yasuhito Uezono; Tsutomu Suzuki; Minoru Narita
Journal:  Mol Pain       Date:  2016-06-17       Impact factor: 3.395

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.